Michal Minár, Peter Valkovič
Restless legs syndrome (RLS) is a neuropsychiatric disorders with nightime symptoms that have negative impact on
sleep, leading to reduced quality of life. Prevalence in general population is high, and is estimated to be about 7 %. Recent
scientific data suggest that iron deficiency in central nervous system leads to dopaminergic dysfunction. According
to these facts, together with clinical practise and results of placebo-controlled trials, dopaminergic substances, anticonvulsants,
and opioids are used in RLS treatment. We report on two patients with RLS refractory to first-line medication,
finally succesfully treated with fixed combination of oxycodone/naloxone.